Study #2024-0216
A phase 2, open-label, multicenter study of IBI363 (PD1-IL2m) alone or in combination with standard of care therapy in participants with advanced solid malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
IBI363
Description
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Study phase:
Phase II
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.